Which has stronger earnings and valuation, ACIU or ANNX?

AC Immune has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 54.43 -$85.03M -$0.54 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is ACIU or ANNX more profitable?

Annexon has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Annexon N/A -101.19% -75.99%

Does the media favor ACIU or ANNX?

In the previous week, AC Immune had 5 more articles in the media than Annexon. MarketBeat recorded 9 mentions for AC Immune and 4 mentions for Annexon. AC Immune's average media sentiment score of 1.00 beat Annexon's score of 0.72 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABUS or ACIU more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to AC Immune's net margin of -245.32%. Arbutus Biopharma's return on equity of 129.32% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% AC Immune -245.32% -100.17% -28.36%

Does the media refer more to ABUS or ACIU?

In the previous week, AC Immune had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for AC Immune and 1 mentions for Arbutus Biopharma. AC Immune's average media sentiment score of 1.00 beat Arbutus Biopharma's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GERN or ACIU?

Geron has higher revenue and earnings than AC Immune. Geron is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $204.56M 4.63 -$83.50M -$0.11 N/A AC Immune $4.31M 54.43 -$85.03M -$0.54 N/A

Is GERN or ACIU more profitable?

Geron has a net margin of -34.17% compared to AC Immune's net margin of -245.32%. Geron's return on equity of -24.48% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% AC Immune -245.32% -100.17% -28.36%

Does the media prefer GERN or ACIU?

In the previous week, Geron had 17 more articles in the media than AC Immune. MarketBeat recorded 26 mentions for Geron and 9 mentions for AC Immune. AC Immune's average media sentiment score of 1.00 beat Geron's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLDB or ACIU?

In the previous week, AC Immune had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for AC Immune and 5 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.07 beat AC Immune's score of 1.00 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACIU or KURA more profitable?

AC Immune has a net margin of -245.32% compared to Kura Oncology's net margin of -411.19%. AC Immune's return on equity of -100.17% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Kura Oncology -411.19% -141.95% -43.28%

Does the media prefer ACIU or KURA?

In the previous week, AC Immune and AC Immune both had 9 articles in the media. AC Immune's average media sentiment score of 1.00 beat Kura Oncology's score of 0.71 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AC Immune (ACIU) Competitors

$2.31 -0.06 (-2.33%)

As of 01:45 PM Eastern

Compare

ACIU vs. ANNX, ABUS, GERN, SLDB, and KURA

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Annexon (ANNX), Arbutus Biopharma (ABUS), Geron (GERN), Solid Biosciences (SLDB), and Kura Oncology (KURA). These companies are all part of the "biotechnology" industry.

How does AC Immune compare to Annexon?

AC Immune (NASDAQ:ACIU) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

AC Immune has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

AC Immune presently has a consensus target price of $7.50, indicating a potential upside of 225.38%. Annexon has a consensus target price of $15.33, indicating a potential upside of 189.04%. Given AC Immune's stronger consensus rating and higher probable upside, research analysts plainly believe AC Immune is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AC Immune has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	54.43	-$85.03M	-$0.54	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Annexon has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. AC Immune's return on equity of -100.17% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Annexon	N/A	-101.19%	-75.99%

In the previous week, AC Immune had 5 more articles in the media than Annexon. MarketBeat recorded 9 mentions for AC Immune and 4 mentions for Annexon. AC Immune's average media sentiment score of 1.00 beat Annexon's score of 0.72 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AC Immune beats Annexon on 12 of the 15 factors compared between the two stocks.

How does AC Immune compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Arbutus Biopharma has a net margin of 83.95% compared to AC Immune's net margin of -245.32%. Arbutus Biopharma's return on equity of 129.32% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
AC Immune	-245.32%	-100.17%	-28.36%

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 9.29%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 225.38%. Given AC Immune's stronger consensus rating and higher probable upside, analysts clearly believe AC Immune is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Arbutus Biopharma has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	64.19	-$33.50M	$0.83	5.51
AC Immune	$4.31M	54.43	-$85.03M	-$0.54	N/A

In the previous week, AC Immune had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 9 mentions for AC Immune and 1 mentions for Arbutus Biopharma. AC Immune's average media sentiment score of 1.00 beat Arbutus Biopharma's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arbutus Biopharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Summary

Arbutus Biopharma beats AC Immune on 9 of the 16 factors compared between the two stocks.

How does AC Immune compare to Geron?

Geron (NASDAQ:GERN) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

73.7% of Geron shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Geron has a net margin of -34.17% compared to AC Immune's net margin of -245.32%. Geron's return on equity of -24.48% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
AC Immune	-245.32%	-100.17%	-28.36%

Geron has higher revenue and earnings than AC Immune. Geron is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$204.56M	4.63	-$83.50M	-$0.11	N/A
AC Immune	$4.31M	54.43	-$85.03M	-$0.54	N/A

In the previous week, Geron had 17 more articles in the media than AC Immune. MarketBeat recorded 26 mentions for Geron and 9 mentions for AC Immune. AC Immune's average media sentiment score of 1.00 beat Geron's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	5 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Geron currently has a consensus target price of $4.00, indicating a potential upside of 171.19%. AC Immune has a consensus target price of $7.50, indicating a potential upside of 225.38%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Geron and AC Immune tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Solid Biosciences presently has a consensus price target of $17.11, indicating a potential upside of 105.29%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 225.38%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, AC Immune had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for AC Immune and 5 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.07 beat AC Immune's score of 1.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Solid Biosciences' return on equity of -71.35% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
AC Immune	-245.32%	-100.17%	-28.36%

AC Immune has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
AC Immune	$4.31M	54.43	-$85.03M	-$0.54	N/A

Summary

Solid Biosciences and AC Immune tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to Kura Oncology?

AC Immune (NASDAQ:ACIU) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

AC Immune has a net margin of -245.32% compared to Kura Oncology's net margin of -411.19%. AC Immune's return on equity of -100.17% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Kura Oncology	-411.19%	-141.95%	-43.28%

51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, AC Immune and AC Immune both had 9 articles in the media. AC Immune's average media sentiment score of 1.00 beat Kura Oncology's score of 0.71 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 225.38%. Kura Oncology has a consensus target price of $25.46, indicating a potential upside of 164.54%. Given AC Immune's higher probable upside, equities analysts plainly believe AC Immune is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

AC Immune has higher earnings, but lower revenue than Kura Oncology. AC Immune is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	54.43	-$85.03M	-$0.54	N/A
Kura Oncology	$67.48M	12.66	-$278.67M	-$3.35	N/A

AC Immune has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

AC Immune beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$234.58M	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-4.27	9.08	269.97	24.82
Price / Sales	54.43	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.27	17.65	11.26	6.44
Net Income	-$85.03M	-$13.25M	$3.45B	$347.27M
7 Day Performance	3.83%	5.33%	3.62%	2.55%
1 Month Performance	-3.56%	-1.83%	-0.56%	-1.02%
1 Year Performance	7.71%	61.05%	77.38%	23.33%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.6648 of 5 stars	$2.31 -2.3%	$7.50 +225.4%	+10.3%	$234.58M	$4.31M	N/A	140	Positive News Earnings Report
ANNX Annexon	3.6335 of 5 stars	$5.42 +3.1%	$15.33 +183.2%	+129.2%	$887.19M	N/A	N/A	60	Positive News Upcoming Earnings Gap Up
ABUS Arbutus Biopharma	1.0389 of 5 stars	$4.44 +1.7%	$5.00 +12.7%	+36.2%	$876.09M	$14.08M	5.34	90
GERN Geron	2.2121 of 5 stars	$1.35 +5.1%	$4.00 +197.4%	+15.6%	$862.85M	$196.12M	N/A	70	Earnings Report Analyst Revision Gap Down
SLDB Solid Biosciences	2.6966 of 5 stars	$8.67 +8.0%	$17.11 +97.5%	+33.4%	$855.04M	N/A	N/A	100	Positive News Earnings Report Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. ANNX, ABUS, GERN, SLDB, and KURA

How does AC Immune compare to Annexon?

Summary

How does AC Immune compare to Arbutus Biopharma?

Summary

How does AC Immune compare to Geron?

Summary

How does AC Immune compare to Solid Biosciences?

Summary

How does AC Immune compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. ANNX, ABUS, GERN, SLDB, and KURA

How does AC Immune compare to Annexon?

Which has more risk & volatility, ACIU or ANNX?

Do analysts prefer ACIU or ANNX?

Do institutionals & insiders have more ownership in ACIU or ANNX?

Which has stronger earnings and valuation, ACIU or ANNX?

Is ACIU or ANNX more profitable?

Does the media favor ACIU or ANNX?

Summary

How does AC Immune compare to Arbutus Biopharma?

Is ABUS or ACIU more profitable?

Do analysts recommend ABUS or ACIU?

Which has preferable earnings & valuation, ABUS or ACIU?

Does the media refer more to ABUS or ACIU?

Do institutionals and insiders believe in ABUS or ACIU?

Which has more risk & volatility, ABUS or ACIU?

Summary

How does AC Immune compare to Geron?

Do insiders and institutionals believe in GERN or ACIU?

Is GERN or ACIU more profitable?

Which has better valuation and earnings, GERN or ACIU?

Does the media prefer GERN or ACIU?

Which has more volatility and risk, GERN or ACIU?

Do analysts prefer GERN or ACIU?

Summary

How does AC Immune compare to Solid Biosciences?

Do analysts recommend SLDB or ACIU?

Does the media prefer SLDB or ACIU?

Do insiders & institutionals believe in SLDB or ACIU?

Which has more volatility and risk, SLDB or ACIU?

Is SLDB or ACIU more profitable?

Which has better earnings and valuation, SLDB or ACIU?

Summary

How does AC Immune compare to Kura Oncology?

Is ACIU or KURA more profitable?

Do insiders and institutionals have more ownership in ACIU or KURA?

Does the media prefer ACIU or KURA?

Do analysts rate ACIU or KURA?

Which has preferable valuation & earnings, ACIU or KURA?

Which has more risk and volatility, ACIU or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools